It is important to note that our current tau TG mice recapitulate some, but not all, aspects of prototypical Efforts to produce animal models of tau pathologies by directly overexpressing the tau gene have been tauopathies. For example, previous studies have shown that NF proteins are only found in NFTs at late stages limited, but further efforts will be facilitated by the discovery of the FTDP-17 tau gene mutations. Initial reports of the disease in AD patients. Thus, it will be important to generate TG mice that develop filamentous tau tangles described TG mouse lines overexpressing 4R2N or 3R0N human tau using cDNAs driven by Thy-1 and without any associated NF proteins early on in the disease pathogenesis. Our initial rationale for overexpressby 3-hydroxy-3methyglutaryl coenzyme A reductase promoters, respectively. Both of these lines developed ing the smallest 3Rtau in mice is based on the notion that rodents only express 4Rtau and they never develop "pretangle" tau pathology but no filamentous tau inclusions (Goetz et al., 1995; Brion et al., 1999). The lack of tau pathologies spontaneously as they age. Thus, by overexpressing the missing 3Rtau isoform, we thought tau filament formation in the TG models may be due to the low level of transgene expression in these mice.
we might be able to induce NFT formation. However, these mice did not develop tangles identical to NFTs, Notably, intraneuronal injections of tau cDNA containing plasmids followed by the massive overexpression of but they did develop filamentous tau inclusions that were comprised almost exclusively of 3Rtau, much like 4R2N human tau have been shown to lead to the formation of PHFtau-like filamentous inclusions and the dethose found in PiD and the FTDP-17 kindred with the ⌬280K tau mutation. generation of some affected neurons in the lamprey central nervous system (Hall et al., 1997) . Encouraged Other TG mice must be generated that exploit the FTDP-17 tau gene mutations, and these mice should by these results, we recently produced TG mouse lines that express 5-to 15-fold higher levels of wild-type (WT) provide important insights into how the mutations cause loses of normal tau function, toxic gains of function, or human 3R0N tau than endogenous mouse tau. These mice developed argyrophilic (silver positive) inclusions both. Further, it also is critical to develop tau TG mice using glial-as well as neuron-specific promoters to formed by aggregated 10-20 nm filaments composed of tau and neurofilament (NF) proteins (Ishihara et al., drive transgene expression, since oligodendrocytes and astrocytes as well as neurons accumulate tau tangles 1999 [this issue of Neuron]). However, these filaments did not exhibit the ultrastructural features of PHFs in in many tauopathies. Thus, by developing tau TG mouse models that acquire glial tau pathology, it will be possiclassic AD NFTs, although tau protein isolated from brain and spinal cord of these mice became progresble to investigate the contribution of glial tangles in neurodegenerative tauopathies. Additionally, since all sively insoluble and more phosphorylated with advancing age. Further, the accumulation of these tau-rich lesix tau isoforms are present in the adult human brain and since many of the FTDP-17 tau gene mutations sions in the tau TG mice is transgene dose dependent and age dependent. Most significantly, these TG mice affect E10 splicing through multiple mechanisms, it also is highly desirable to develop TG animals with and withdeveloped a phenotype more similar to that seen in tauopathies such as FTDP-17, PSP, and ALS/PDC, out E10 splice mutations using the P1-derived artificial chromosome (PAC) containing the entire tau gene. The rather than that seen in AD, since the tau pathologies in these TG mice were more abundant in spinal cord WT and mutant tau PAC animals will be invaluable in studies of the alternative splicing of the tau gene and and brain stem. The spinal cord inclusions were associated with axonal degeneration in related spinal cord how altered splicing results in tau pathologies as well as age-dependent neurodegeneration. Additional and perhaps more authentic TG mouse models of tauopathies could be developed by crossing PAC mice harboring intronic or exonic FTDP-17 tau gene mutations with tau gene knockout mice to generate "humanized" tau TG lines. Finally, it would be desirable to produce model systems that more accurately recapitulate the hallmark pathology of AD by crossing the various tau TG mice with TG mouse models of AD A␤ amyloidosis. Accordingly, by producing TG mouse models designed to exploit the new insights into the pathobiology of tauopathies discussed here, it should be possible to make rapid progress in elucidating how and why glial and neuronal tau pathologies lead to the onset and progression of sporadic and hereditary neurodegenerative diseases characterized by prominent filamentous tau inclusions.
